36 results about "Intrahepatic Cholangiocarcinoma" patented technology

The invention relates to a pharmaceutical nanometer composite temperature-sensitive gel for treating a biliary tract tumor. The gel is made by coating nanometer particles made from an anti-tumor active substance with a polymer or a targeted-gene-modified polymer which is taken as a carrier material, and adding a temperature-sensitive polymer material to prepare nanometer composite temperature-sensitive gel, or dissolving or suspending the anti-tumor active substance nanometer particles in temperature-sensitive gel. The gel is simple to prepare, is suitable for massive production, and is suitable for preparing a medicine for treating and preventing biliary tract tumors, such as gallbladder carcinoma, intrahepatic cholangiocarcinoma and cholangiocarcinoma, which relapse after operation.

The invention discloses a product and a method for identifying hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on an MANF as a marker. The invention provides an application of a system for detecting the expression quantity of the MANF in preparation of products for identification or supplementary identification of hepatocellular carcinoma patients and intrahepatic cholangiocarcinoma patients. The hepatocellular carcinoma and the intrahepatic cholangiocarcinoma are identified by taking the MANF as the marker and detecting the expression level of the MANF in a primary hepatocellular carcinoma tissue, a method and an index for effectively identifying the hepatocellular carcinoma and the intrahepatic cholangiocarcinoma are built, the sensitivity is 92.5% and the specificity is 74.7%. A foundation is laid for targeted appropriate treatment and improvement of prognosis of the patients to improve the living quality of the patients and to reduce the economic burden of the patients.

The invention discloses an application of a substance taking MANF as a target spot in preparing products for treating intrahepatic cholangiocarcinoma. An experiment proves that the substance for inhibiting MANF expression in cells or inhibiting MANF activity in cells is capable of effectively inhibiting the multiplication, migration and/or invasion of cholangiocarcinoma cells, is capable of inhibiting the growth of cholangiocarcinoma and can be used for treating or/and preventing intrahepatic cholangiocarcinoma.

The invention relates to a human intrahepatic cholangiocarcinoma cell line with high tumorigenic ability and application thereof. The invention discloses a novel human intrahepatic cholangiocarcinoma cell line which grows stably and has clear quantity of generations and high tumorigenic rate; the human intrahepatic cholangiocarcinoma cell line can form an adenoid tumor in vivo and can be used for in-vivo and in-vitro research on human intrahepatic cholangiocarcinoma; a foundation is laid for constructing an in-vivo animal model, disclosing a tumor malignant progression mechanism, screening related biomarkers and developing novel intrahepatic cholangiocarcinoma resisting medicines.

The invention discloses an application of splenic tyrosine kinase as a therapeutic target for intrahepatic cholangiocarcinoma. Experiments find out that the expression of SYK in intrahepatic cholangiocarcinoma is increased. In-vitro cell and in-vivo animal experiments find out that the proliferation of intrahepatic cholangiocarcinoma can be effectively inhibited with the use of the SYK antagonistGS-9973, and the inhibiting effect is close to that of a first-line chemotherapeutic drug gemcitabine.

The invention discloses a prognosis detection biomarker and a detection kit for an intrahepatic cholangiocarcinoma patient. A set of polynucleotide sequences shown as SEQ ID NO.1 -SEQ ID NO.24 is taken as a biomarker, methylation analysis is performed on promoter regions, an effective methylation scoring model is constructed, and accurate evaluation of prognosis lifetime of the intrahepatic cholangiocarcinoma patient is realized. The biomarker can be used as a single prediction factor for prognosis of the patient suffering from the intrahepatic cholangiocarcinoma, and can also be used for predicting the prognosis lifetime of the patient suffering from the intrahepatic cholangiocarcinoma based on a plurality of variables including methylation scores of gene promoters.

The invention provides a construction method of a model for predicting the survival rate of a patient with intrahepatic cholangiocarcinoma. The construction method comprises the following steps of 1)providing DNA methylation sequencing data of the intrahepatic cholangiocarcinoma; 2) analyzing the DNA methylation sequencing data, and screening out a plurality of related promoter regions of the intrahepatic cholangiocarcinoma; and 3) establishing a model for predicting the survival rate of the intrahepatic cholangiocarcinoma patient by utilizing the plurality of related promoter regions of theintrahepatic cholangiocarcinoma. By conducting DNA methylation prognostic labeling on intrahepatic cholangiocarcinoma patients, the DNA methylation markers serve as independent variables, the patientsare distinguished into a high death rate group and a low death risk group, and experimental verification shows that the construction method of the model can be used for predicting the total postoperative survival rate of the intrahepatic cholangiocarcinoma patients, and can be used for predicting the postoperative survival rate of the intrahepatic cholangiocarcinoma patients; an individualized adjuvant therapy strategy is provided for a patient with the intrahepatic cholangiocarcinoma.

The invention discloses an FISH probe set for detecting FGFR2 fusion and application thereof. The probe set comprises a 5' end probe set and a 3' end probe set; the 5' end probe set adopts BAC of a nucleotide of one side of an FGFR2 gene telomere as a template through cloning and is obtained by amplifying random primers, and each probe is modified with a first reporter group; the 3' end probe setis obtained by cloning the BAC of the nucleotide sequence of the centromere side of the FGFR2 gene into a template and amplifying the random primers, and each probe is modified with a second reportergroup. The set has the advantages of rapid and simple operation, accurate and reliable detection result and accurate detection of all fusion types of the FGFR2 gene, provides a reference for the treatment of intrahepatic cholangiocarcinoma patients, is beneficial to individualized targeted therapy of the patients, reduces drug side effects, improves patient survival quality, reduces the burden onfamilies and society, and is suitable for large-scale promotion and application.

The invention provides an intrahepatic cholangiocarcinoma patient prognosis lifetime prediction system, which comprises an acquisition module and a prediction module, and is characterized in that theacquisition module and the prediction module are connected in a wireless and/or wired mode. The prediction system can predict the prognostic lifetime of the intrahepatic cholangiocarcinoma patient byadopting the promoter methylation score as a unique variable, can predict the prognostic lifetime of the intrahepatic cholangiocarcinoma patient based on multiple variables including the promoter methylation score, and has the advantages of high accuracy, strong reliability and stable prediction.

The invention discloses a marker for evaluating the gemcitabine chemosensitivity and/or prognosis of intrahepatic cholangiocarcinoma and application of the marker. The marker for evaluating the gemcitabine chemosensitivity and/or prognosis of intrahepatic cholangiocarcinoma is CXCR3 expressed on the surfaces of peripheral blood leukocytes or immune cells in cholangiocarcinoma tissues of an intrahepatic cholangiocarcinoma patient. A kit for evaluating the gemcitabine chemosensitivity and/or prognosis of intrahepatic cholangiocarcinoma comprises a reagent related to detection of the expression quantity of the CXCR3 protein. A method for evaluating the gemcitabine chemosensitivity and/or prognosis of intrahepatic cholangiocarcinoma comprises the following steps: (1) detecting the expression quantity of CXCR3 on the surfaces of peripheral blood leukocytes or immune cells in cholangiocarcinoma tissues of an intrahepatic cholangiocarcinoma patient; and (2) comparing the expression quantity with a preset CXCR3 protein expression quantity threshold value, evaluating that the patient is sensitive to gemcitabine chemotherapy and/or good in prognosis of gemcitabine chemotherapy if the CXCR3 protein expression quantity is higher than the threshold value, and otherwise, evaluating that the patient is insensitive to gemcitabine chemotherapy and/or poor in prognosis of gemcitabine chemotherapy.

The invention relates to the technical field of medical biological detection, and concretely relates to application of human thrombin-sensitive protein-1 in preparation of a kit for predicting the chemotherapy effect of intrahepatic cholangiocarcinoma. The application has the advantages that the protein chip is used for screening out the protein with expression difference in tissues of patients of an intrahepatic cholangiocarcinoma (ICC) chemotherapy drug-resistant group and an ICC chemotherapy sensitive group in the middle and advanced stages, the protein can be detected in serum, and it is found that the thrombin-sensitive protein-1 has the most obvious difference in two groups of patients and has a very high expression level in sensitive group patients. The invention provides the application of human thrombin-sensitive protein-1 as a serum marker for determining whether chemotherapy of an intrahepatic cholangiocarcinoma patient is sensitive or not. The expression level of the human thrombin-sensitive protein-1 is closely related to survival prognosis of the patient. The application provides a new clinical means for serological diagnosis.

The invention discloses application of circular RNA cGGNBP2, and provides a kit for diagnosing intrahepatic cholangiocarcinoma and a pharmaceutical composition for treating the intrahepatic cholangiocarcinoma based on the function and mechanism research of the inventor on the circular RNA cGGNBP2 (circBase ID: hsa_circ_0003930) in growth and metastasis of hepatic cholangiocarcinoma cells. The invention also discloses application of the circular RNA cGGNBP2 as a therapeutic target in prognosis, diagnosis and treatment of intrahepatic cholangiocellular carcinoma.

The invention relates to the technical field of biomedical engineering, and discloses application of SLC12A5 and an inhibitor of the SLC12A5. The biological function of the SLC12A5 is inhibited through the specific inhibitor, and compared with a control group, the SLC12A5 inhibitor can significantly inhibit bile duct cancer cell proliferation and clone formation rate, and also can significantly inhibit subcutaneous tumor growth, so that therefore, a new way for preparing the medicine for treating or improving the intrahepatic cholangiocarcinoma and treating the intrahepatic cholangiocarcinoma can be provided by taking the SLC12A5 as the target spot.

The invention provides a diagnosis method and diagnosis kit for intrahepatic cholangiocarcinoma. The kit comprises primers and probe aiming at mutant type glypican 3 (GPC3) complementary DNA (cDNA). According to the diagnosis method and the diagnosis kit, experiments show that the glypican 3 can mutate in the intrahepatic cholangiocarcinoma; the mutation has specificity in the intrahepatic cholangiocarcinoma, and therefore, the mutant GPC3 cDNA can be used as a specific marker for diagnosing and treating an acute liver injury with drugs. Based on the above, the invention provides a new hepatocyte diagnosis method and kit.